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CCDC88B is required for pathogenesis of
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Inﬂammatory bowel disease (IBD) involves interaction between host genetic factors and
environmental triggers. CCDC88B maps within one IBD risk locus on human chromosome
11q13. Here we show that CCDC88B protein increases in the colon during intestinal injury,
concomitant with an inﬂux of CCDC88B+lymphoid and myeloid cells. Loss of Ccdc88b
protects against DSS-induced colitis, with fewer pathological lesions and reduced intestinal
inﬂammation in Ccdc88b-deﬁcient mice. In a T cell transfer model of colitis, Ccdc88b mutant
CD4+ T cells do not induce colitis in immunocompromised hosts. Expression of human
CCDC88B RNA and protein is higher in IBD patient colons than in control colon tissue. In
human CD14+ myeloid cells, CCDC88B is regulated by cis-acting variants. In a cohort of
patients with Crohn’s disease, CCDC88B expression correlates positively with disease risk.
These ﬁndings suggest that CCDC88B has a critical function in colon inﬂammation and the
pathogenesis of IBD.
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Inﬂammatory bowel diseases (IBD) are heterogeneous inﬂam-matory diseases that affect the gastrointestinal tract. InCrohn’s disease (CD) the ileum and colon are primarily
affected, whereas in ulcerative colitis (UC) only the distal colon is
affected. Both genetic factors and environmental effects (life style,
diet, intestinal ﬂora) contribute to IBD pathogenesis. Genetic
studies of patients with rare early onset and severe forms of IBD
have uncovered >60 causative genes and associated mutations,
and genome wide association studies (GWAS) have mapped
>200 non-MHC linked loci that affect susceptibility to IBD1–4.
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However, the effect size and contribution to disease of individual
GWAS loci is small; for many IBD loci the causative gene and
mechanistic basis of the genetic effect are unknown.
In a forward genetic screen in mice, we identiﬁed that Ccdc88b
is required for pathological and lethal neuroinﬂammation5. In
mice, Ccdc88b mRNA transcripts are almost exclusively present
in haematopoietic organs and the Ccdc88b protein is expressed in
CD4+ T cells, CD8+ T cells and myeloid cell subsets5. Ccdc88b
mutant (Ccdc88bm1PGrs) T cells have impaired maturation in vivo,
and reduced activation, cell division and cytokine production
(IFNγ, TNF) in response to speciﬁc or non-speciﬁc stimuli
in vitro5. CCDC88B belongs to the hook-related protein family
(CCDC88A, CCDC88B, CCDC88C), which is deﬁned by a con-
served region similar to the microtubule binding domain of Hook
proteins6. The function of these proteins is unclear, but they seem
to functionally couple elements of the cytoskeleton with different
cellular processes, such as vesicular transport and cell movement6.
Ccdc88b has been shown to interact with the CDC42 guanine
nucleotide exchange factor DOCK87. Human DOCK8 mutations
cause primary immunodeﬁciencies associated with perturbed
migration, altered function of myeloid and NK cells8,9. CCDC88B
(HkRP3) is also required for NK cell cytotoxicity including pro-
duction and mobilization of cytotoxic granules8.
Human CCDC88B maps to distal chromosome 11 (11q13)
within a locus associated with susceptibility to several inﬂamma-
tory conditions10, including sarcoidosis11, IBD1, psoriasis12, alo-
pecia areata13, multiple sclerosis14 and primary biliary cirrhosis15.
The 11q13 locus contains >23 genes in linkage disequilibrium on
a 1Mb segment, making it difﬁcult to identify the gene underlying
the pleiotropic effect of this locus on inﬂammatory diseases.
Epigenetic annotation based on recruitment, and transcriptional
activation by proinﬂammatory factors IRF1, IRF8, and STAT1 in
response to exposure of myeloid cells to IFNγ (myeloid inﬂam-
mation score)16, has been used to identify CCDC88B as the top
“inﬂammatory” positional candidate at 11q135.
Here, we show that Ccdc88b+ lymphoid and myeloid cells are
recruited to the site of inﬂammation in experimental colitis.
Furthermore, Cccdc88b mutant mice are protected against DSS-
induced colitis, and naive Ccdc88b mutant CD4+ T cells do not
induce colitis in immunocompromised mice. In humans,
CCDC88B mRNA and protein expression is increased in inﬂamed
colons of patients with UC or CD. In human CD14+ cells,
CCDC88B mRNA is regulated by cis-acting regulatory SNPs (that
is, eQTL), and eQTL effects and disease risk are correlated, with
increased CCDC88B expression associated with increased risk.
Our study therefore identiﬁes a critical function of CCDC88B in
colonic inﬂammation and IBD.
Results
CCDC88B expression is induced during experimental colitis.
The role of CCDC88B in intestinal homeostasis and in patholo-
gical inﬂammation was investigated in the dextran sodium sulfate
(DSS) mouse model of intestinal colitis. We found that Ccdc88b
mRNA levels gradually increased in the colon of DSS-treated
wild-type (WT) mice at day 4 and day 8 following initiation of
DSS treatment, when compared to untreated mice (Fig. 1a).
Likewise, Ccdc88b protein level was increased at day 4 and day 8
post-treatment whereas no Ccdc88b expression was detected in
the colon of Ccdc88b mutant mice at day 8 (Fig. 1b and Sup-
plementary Fig. 7a). To investigate the tissue and cell types that
express Ccdc88b in the colon during colitis, we performed
immunohistochemistry and found Ccdc88b staining in a sub-
population of cells that are also positive for the hematopoietic
marker CD45 (Fig. 1c). Interestingly, the rest of the E-cadherin
positive intestinal mucosa and associated epithelium were nega-
tive for Ccdc88b (Fig. 1c). Furthermore, ﬂow cytometry analysis
(FACS) of mononuclear cells isolated from colons show a sig-
niﬁcant increase of CD45+Ccdc88b+ cells at day 8 after DSS,
conﬁrming recruitment of Ccdc88b+ inﬂammatory cells (Fig. 1d).
Immunoﬂuorescence and ﬂow cytometry studies show that
Ccdc88b+ inﬁltrating cells belong to both the lymphoid (CD3+,
CD4+, CD8+) and the myeloid (CD11b+) compartments (Fig. 1e,
f). Further FACS analysis of inﬁltrating cells subsets identiﬁed
increased recruitment of Ccdc88b+ T cells, NK cells, neutrophils,
inﬂammatory monocytes and macrophages at both day 4 and day
8 post DSS treatment (Supplementary Fig. 1). These ﬁndings
indicate that during experimental colitis with DSS in mice,
Ccdc88b+ lymphoid and myeloid cells are recruited to the site of
inﬂammation.
Ccdc88b mutant mice are protected from experimental colitis.
To directly assess whether CCDC88B plays a functional role in
colitis, we subjected WT and Ccdc88b mutant (Ccdc88bmut) mice
to 3% DSS for 5 days followed by water for 3 days and evaluated
colitis incidence (Fig. 2). Ccdc88bmut mice showed signiﬁcantly
less body weight loss when compared to WT mice (Fig. 2a), and
displayed signiﬁcantly longer colons at day 8 post-treatment
(Fig. 2b). Analysis of hematoxylin and eosin stained colon tissue
sections revealed greater repair of the epithelial barrier and
colonic crypts, thinner underlying muscle layer, and less abun-
dant cellular inﬁltration in DSS-treated Ccdc88bmut mice com-
pared to controls (Fig. 2c). Histopathological assessement of a
number of cellular and tissue phenotypes associated with colitis
were quantiﬁed at day 4 and day 8 post-DSS treatment and
conﬁrmed reduced pathology and protection against DSS-
induced colitis in Ccdc88bmut mice (Fig. 2d). At both days 4
and 8, Ccdc88bmut mice had lower inﬁltration of inﬂammatory
cells, and reduced overall pathology measured by submucosal
edema, gland loss and surface erosion and ulceration when
compared to WT (Fig. 2e). No such differences in tissue archi-
tecture and histology were seen in untreated mice of either gen-
otype (Fig. 2c).
Chemokines, such as MCP-1 and RANTES play critical roles in
recruitment of pro-inﬂammatory cells to the site of lesions in
Fig. 1 Mouse Ccdc88b expression in colon during DSS-induced colitis. Wild type (WT) mice were either not treated (NT) or given 3% DSS for 5 days
followed by 3 days of water. a Ccdc88bmRNA expression in distal colons of NT (n= 3) or DSS-treated WT mice (n= 3 for each time point) at the indicated
days. Data represent expression relative to hprt±SEM (n= 3). *P< 0.05, **P< 0.01 (two-tailed Student’s t-test) and are representative of one experiment.
b Representative immunoblots for Ccdc88b protein detected in extracts from distal colons from NT or DSS-treated WT and Ccdc88Bmut mutant mice at
indicated time points, and densitometric quantiﬁcation of Ccdc88b immunoblot normalized to β-actin±SEM (n= 3) (representative of one of two
independent experiments); **P< 0.01 (two-tailed Student’s t-test). c Representative confocal microscopy images of tissue sections from colon of NT or
DSS-treated mice at indicated times, and stained with antibodies against Ccdc88b (red), CD45 (green), and E-Cadherin (purple) and nuclei staining DAPI
(blue). Scale bars, 100 μm. d Representative FACS plots and quantiﬁcation of lamina propria cells stained for CD45 and for Ccdc88b antibodies for NT (n
= 3) and DSS-treated WT mice (n= 4 for each time point) at indicated time points, data are representative of one experiment. e Representative confocal
microscopy images of tissue sections from colon of NT or DSS-treated mice at day 8, and stained for Ccdc88b (red), CD3 (green) and CD11b (green);
nuclei are stained with DAPI (blue). Scale bars, 100 μm. f same as in e for Ccdc88b (red), CD4 (green) and CD8 (green). Scale bars, 100 μm
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patients and in mouse models of IBD17–19. We evaluated mRNA
expression for different pro-inﬂammatory cytokines and chemo-
kines in colons of DSS-treated mice at days 4 and 8. We found
reduced expression of macrophage and neutrophil chemoattrac-
tants MCP1 and KC and of pro-inﬂammatory cytokines IL1β,
TNF and IL6 mRNAs in colons from Ccdc88bmut mice compared
to WT at day 4 after DSS treatment (Fig. 3a). Similar results were
observed at day 8, with MCP1, TNF and RANTES being
signiﬁcantly lower in Ccdc88bmut mutants. The serum levels of
MCP1 and KC, were also signiﬁcantly decreased in Ccdc88bmut
mice compared to WT at day 4, with this difference persisting at
day 8 for KC (Fig. 3b). Compared to WT mice, the epithelium of
treated Ccdc88bmut mice remained relatively intact with increased
cell proliferation and greater number of mucin-containing
epithelial goblet cells assesed by Ki-67 and Alcian blue (mucus)
staining, respectively (Fig. 3c, d). Hence, Ccdc88bmut mice are
protected against DSS-induced colitis, exhibiting less severe
pathology and reduced inﬂammation.
Furthermore, we crossed Ccdc88bmut mice to Rag1−/− mice and
subjected these mice to an acute DSS treatment. We found that
Rag1−/− mice lacking functional Ccdc88b recovered from
DSS-induced colitis (increased body weight, lower colonic
damage, better total pathology scores) faster and more fully
when compared to control Rag1−/− mice (Supplementary Fig. 2).
These results suggest that the absence of Ccdc88b in
innate immune cells is sufﬁcient to dampen epithelial barrier
dammage, decrease inﬂammation and protect against experi-
mental colitis.
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Fig. 2 Loss of Ccdc88b protects against DSS-induced colitis. a WT (n= 14) and Ccdc88bmut mice (n= 14) were treated with DSS (see legend to Fig. 1) and
body weight loss is expressed as percent of initial weight±SEM. ***P< 0.001 (two-tailed Student’s t-test). b Representative images of colons fromWT and
Ccdc88bmut mice at day 8, and quantiﬁcation of effect of treatment on colon length±SEM. ***P< 0.001 (two-tailed Student’s t-test). a, b Data are pooled
from 2 independent experiments. c Hematoxylin and eosin (original magniﬁcation ×10) staining of colon sections from untreated and DSS-treated WT and
Ccdc88bmut mice at the indicated times. Scale bars, 100 μm. d Total pathology score (0–24) fromWT and Ccdc88bmut mice at day 4 after DSS treatment (n
= 5) and day 8 (n= 10)± SEM. **p< 0.01 (Mann–Whitney test). e Histology scores from WT (n= 5 for day 4 and n= 10 for day 8) and Ccdc88bmut (n= 3
for day 4 and n= 10 for day 8) mice at indicated days evaluating inﬂammatory cell inﬁltration, submucosal edema, gland loss and surface epithelial
erosion/ulceration and (Supplementary Table 1) for scoring details (mean±SEM; *P< 0.05, **P< 0.01, and ***P< 0.001; Mann–Whitney test)
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Ccdc88b is required for T cell-induced colitis. We have pre-
viously shown that the Ccdc88b protein is expressed in CD4+ and
CD8+ T cells, and is required for T cell maturation and activa-
tion5. We examined the effect of Ccdc88b mutation on the
capacity of naïve CD4+ T cell (CD4+CD45RBhi cells, (Supple-
mentary Fig. 3)) to induce colitis upon adaptive transfer into
lymphopenic mice20. As previously reported20, Rag1−/− mice
receiving WT CD4+CD45RBhi cells developed symptoms of
colitis including signiﬁcant weight loss by week 6 post transfer
(Fig. 4a). In contrast, Ccdc88bmut CD4+ T cells in Rag1−/−mice
failed to induce similar outcomes including weight loss and colon
shortening (Fig. 4a, b). Histopathological assessment (Fig. 4c, d)
of both groups of Rag1−/− mice receiving either Ccdc88bmut or
WT CD4+ T cells showed the former to display signiﬁcantly less
thickening of the mucosa, lower number and extent of cellular
inﬁltration, number of abscesses and amount of glandular loss
(Fig. 4d). The overall pathology score was signiﬁcantly lower in
Rag1−/− mice receiving Ccdc88bmut vs. WT CD4+ T cells,
demonstrating less severe colitis in the former group (Fig. 4e).
Finally, the attenuated inﬂammation in Rag1−/−mice receiving
Ccdc88bmut CD4+ T cells was associated with lower staining of
T cells than observed in mice receiving WT CD4+ T cells (Fig. 4f).
Our results indicate that Ccdc88b is required for the induction of
gut inﬂammation in the T cell transfer model of colitis.
CCDC88B expression by CD14+ cells correlates with IBD risk.
Human CCDC88B maps to an IBD susceptibility locus on chro-
mosome 11 (11q13)1. Analysis of published genetic association
data in CD patients1 revealed signiﬁcant disease association with
SNPs from a 600 kb region overlapping CCDC88B association,
with the top marker (rs641168; p= 2.1×10−6 using a logistic
regression analysis) located 38.5Kb downstream CCDC88B tran-
scription start site (Fig. 5a). Meta-analysis (combining GWAS
and Immunochips datasets) showed a maximum association
p value of 4.22 10−9 (top marker rs559928) at the CCDC88B
locus1. Parallel analysis of CCDC88B mRNA expression in indi-
vidual cell populations (CD4+, CD8+, CD14+, CD15+, CD19+)
from PBMCs of 320 healthy individuals showed robust but
variable CCDC88B mRNA expression in CD14+ and CD15+ cells
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Fig. 3 Loss of Ccdc88b on inﬂammatory response to DSS-induced colitis. WT and Ccdc88bmut mice were treated with 3% DSS for 5 days followed by 3 days
of water. a Relative expression levels of indicated cytokine and chemokine mRNAs extracted from WT and Ccdc88bmut colon mice at day 4 (n= 5) and day
8 (n= 10) following DSS treatment (mean±SEM; *P< 0.05, **P< 0.01; two-tailed Student’s t-test). b Proinﬂammatory cytokine MCP1 and KC were
quantiﬁed in serum by ELISA, and results are presented in ng/ml (mean± SEM; ***P< 0.001; two-tailed Student’s t-test). a, b Data are pooled from 2
independent experiments. c Representative image (n= 4) of crypt regeneration visualized by Ki-67 staining (hematoxylin counterstaining), Scale bars, 100
µm. d Representative image (n= 4) of epithelial integrity by mucin staining (Alcian blue) of colons from DSS-treated mice at day 8. Scale bars, 100 µm
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(Supplementary Fig. 4a). eQTL analysis can be used to identify
relevant variant:gene pairing among potential combinations of
SNPs mapped by GWAS and the adjacent genes21. Because
genotype information was available for these individuals, we
analyzed the possible effect of 11q13 SNPs near CCDC88B on
expression of the gene in these PBMC cell populations. We noted
an effect of several SNPs in this region on CCDC88B mRNA
expression in CD14+ cells, with the top marker (rs146881600; p
= 0.0016) mapping at 6Kb from rs641168 and 32 Kb from
CCDC88B (Fig. 5b). If the genetic associations observed for this
chromosomal region with CD on the one hand and CCDC88B
expression on the other hand are causally related, one predicts
that the corresponding association patterns (i.e. the log(1/p)
values for all SNPs in the region for CD and CCDC88B expres-
sion, respectively) may be similar. Thus, we investigated a pos-
sible correlation between the strength of the cis-acting eQTLs
effect on CCDC88B expression in CD14+ cells, and strength of the
association of the same SNPs with disease in our cohort of CD
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patients (Fig. 5c) (Equation 1, Methods). This analysis identiﬁes a
signiﬁcant correlation (accounting for LD in the region) between
eQTLs effects on CCDC88B expression and association (in
GWAS dataset) with CD disease risk (p> 0.01), with increased
CCDC88B expression associated with increased risk (Fig. 5c). A
similar analysis performed for CD4+, CD8+, CD15+ and CD19+
cell subsets failed to identify such a correlation between eQTL
effects on CCDC88B mRNA expression in these cell subsets and
association with CD risk (in GWAS datasets) (Supplementary
Fig. 4b). These results strongly suggest that differences in the level
of expression of CCDC88B expression (eQTL) in CD14+ cells are
associated with variable risk of IBD.
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11q13. Log(1/p) values are given for all SNPs positioned on the human hg18 build1. The association signal was maximal for rs641168 (P= 2.1 × 10-6, using a
logistic regression analysis). Gene names and positions are shown under the graph. b eQTL association pattern for CCDC88B expression in CD14+ cells for
the same chromosome region as in a. The association signal was maximal for rs146881600 (P= 0.0017, using a logistic regression analysis). c Correlation
between the disease and eQTL association patterns. Two data points are shown for each “informative” SNP (i.e., with data in both analyses and log(1/p)
value ≥1.2 with either disease, eQTL or both). One corresponds to log(1/p) values (disease and eQTL) multiplied by the signs of the effects of allele 1, the
other with the log(1/p) values multiplied by the signs of the effects of allele 2. The observed correlate was shown to be signiﬁcant (P= 0.01, by a logistic
regression analysis) using the approach described in the Methods section
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CCDC88B is increased in colons from IBD patients. We further
evaluated CCDC88B mRNA and protein levels in colon surgical
specimens obtained from UC patients (UC; n= 46) and CD
patients (CD; n= 11), and from normal controls, consisting of
non-inﬂamed areas of the colon of patients with colorectal cancer
or diverticulitis (n= 73). We found a higher expression of
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Fig. 6 CCDC88B expression in inﬂamed colons from patients with IBD. a CCDC88B mRNA expression in colon tissue samples extracted from surgical
specimens of patients with Crohn’s Disease (CD, n= 11), Ulcerative colitis (UC, n= 46) or normal control (NL, n= 73). Data represent expression of
CCDC88B relative to the ribosomal protein L32 (mean±SEM; **P< 0.01, ***P< 0.001; two-tailed Student’s t-test). b Immunoblot analysis of CCDC88B and
β-ACTIN performed on colonic tissue extracts obtained from surgical specimens of patients with CD (n= 4), UC (n= 4) or NL controls (n= 4). Each lane
denotes an individual patient sample. Densitometric quantiﬁcation of CCDC88B and β-actin immunoblots. Bar graphs represent normalized relative density
of each lane (n= 4 patient samples). c IL-8 mRNA expression in colon tissues samples from CD (n= 69), UC (n= 7) and NL (n= 38). Data represent
expression of IL8 relative to the ribosomal protein L32 (mean±SEM; **P< 0.01, ***P< 0.001; two-tailed Student’s t-test). d, e Immunoﬂuorescence staining
of CCDC88B, CD4 and CD68 in colon tissue sections from patients with CD, UC, or NL controls (CCDC88B, red; nuclei blue staining with Hoechst).
Isotype control staining for each section is shown. Scale bars, 100 µm and 10 µm
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CCDC88B mRNA in the colon of patients with IBD in both CD
and UC in comparison with non-inﬂamed mucosa (Fig. 6a). By
immunoblotting, using a speciﬁc antibody against human
CCDC88B (Supplementary Fig. 5) in a subset of colon surgical
specimens, we found CCDC88B protein signiﬁcantly increased in
inﬂamed colons of CD and UC patients compared to non-
inﬂamed controls (Fig. 6b and Supplementary Fig. 7b). We also
quantiﬁed expression of the pro-inﬂammatory cytokine IL-8 in a
subset of clinical specimens consisting of 69 controls, 7 CD and
38 UC samples; we deetcted increased IL-8 expression in speci-
mens from CD and UC patients compared to NL controls
(Fig. 6c).
We used immunohistochemistry to examine the site of
CCDC88B protein expression in inﬂammaed mucosa from IBD
patients. First, to conﬁrm the inﬂamed nature of the tissue
samples used in our experiments, blind histological scoring was
performed on H&E sections. Apparent chronic inﬂammation and
active inﬂammation were observed in the colon mucosa of UC
and CD patients (Supplementary Fig. 6a), and was paralleled with
increased presence of CD3+ and CD8+ cells (Supplementary
Fig. 6b). CCDC88B expression in inﬂamed mucosa was limited to
non-epithelial cells in the lamina propria, and colocalised with
CD4+ and CD68+ inﬁltrating immune cells (Fig. 6d, e). These
CCDC88B+ cells were found in greater numbers in the mucosa
from patients with CD and UC compared to non-inﬂamed
controls (Fig. 6d, e). Hence, our data show that human CCDC88B
is highly expressed in colon lamina propria cells of inﬂammed
mucosa from UC and CD patients, with its expression limited to
inﬁltrating lymphoid and myeloid cells.
Discussion
We have previously shown that a mutation in Ccdc88b protects
mice against lethal neuroinﬂammation in models of microbial
disease5. In these studies, the loss of Ccdc88b did not affect the
number of lymphoid and myeloid cells, but it impacted the
maturation, and activation of these cells including production of
pro-inﬂammatory cytokines5. Here we show that a mutation in
Ccdc88b protects mice against experimental intestinal colitis, both
in the DSS-colitis and CD4 T cells transfer models. Studies of the
mouse model of colitis have clearly shown that reduced inﬂam-
mation in situ decreases pathogenesis22. In these models, it has
been reported that secretion of of IL-1β, IL-6, IL-9, and TNF
drives pathogenesis22–25. In the absence of Ccdc88b, we found
that the protection is associated with reduced recruitment of
hematopoietic cells to the site of inﬂammation, concomitant to
reduced local and systemic production of pro-inﬂammatory
cytokines. In the CD4 T cell transfer model20, absence of Ccdc88b
expression in CD45RBhi CD4 T cells is associated with protection
against intestinal inﬂammation.
Leukocytes trafﬁcking and recruitment into the inﬂamed
intestine is fundamental to the development of IBD, including
functional interaction between the α4β7integrin expressing T cells
and MAdCAM-1+ gut endothelial cells26–29. How does
CCDC88B may regulate immune cells function during intestinal
inﬂammation? An interesting clue comes from a recent report
documenting physical interaction between CCDC88B (HkRP3)
and the CDC42 guanine nucleotide exchange factor DOCK 87.
DOCK8 mutations cause primary immunodeﬁciencies that clini-
cally manifest as severe allergy, skin and lung infections in
humans8,9. DOCK8 has been shown to be essential for the
homing and function of myeloid (dendritic cells) and NK cells8,9.
In addition, CCDC88B (HkRP3) is required for NK cells cyto-
toxicity and anti-tumor activity in general, and for the production
and mobilization of cytotoxic granules in these cells7. It is
tempting to speculate that CCDC88B may regulate migratory
properties of myeloid and lymphoid cells during intestinal
inﬂammation.
We also show that human CCDC88B mRNA and protein are
increased in colon specimens from IBD patients, and linked to
presence of CCDC88B+ cells in these tissues. In agreement with
previously published results30, we observe that (a) CCDC88B is
genetically linked to susceptibility to IBD, and (b) establish that
the level of CCDC88B mRNA in normal CD14+ but not to other
cells subsets is regulated by cis-acting variants (eSNPs), (c) detect
a signiﬁcant correlation between eQTLs effects and disease risk,
with increased CCDC88B expression associated with increased
risk and (d) observe that CCDC88B+myeloid and lymphoid cell
subsets inﬁltrate the lamina propria of CD and UC patients. The
speciﬁcity of the eQTL effect on CCDC88B mRNA expression in
human CD14+ myeloid cells and its association with IBD disease
risk may seem in apparent contrast to the results obtained in the
RAG/lymphocyte deﬁcient reconstitution model and that support
a role of CCDC88b in T cells function in this mouse model of
intestinal inﬂammation. We believe this points to a key role of
CCDC88B in both lymphoid and myeloid cells, with the former
being critical in this mouse model of inﬂammation, while the
latter is possibly more relevant to the human disease and the
criteria used to establish diagnosis. Indeed, we have previously
demonstrated a role for CCDC88B in the function of both T cells
and myeloid cells in other mouse models of inﬂammation (neu-
roinﬂammation)5.
Our results are compatible with a model in which CCDC88B is
a microtubule associated protein which physically and function-
ally interacts with DOCK8, a protein required for mobility and
homing of lymphoid and myeloid cells. We propose that
genetically regulated levels of CCDC88B in immune cells may
impact the recruitment of these cells to the site of tissue injury,
causing variable inﬂammatory response in situ, and variable
disease pathogenesis. This model is consistent with the pleiotropic
effect of Ccdc88b mutation in different experimental models of
inﬂammation in mice, and the association of the 11q13 locus with
several inﬂammatory diseases in humans.
Methods
Ethics statement. All experiments with live mice conducted in this study were
performed in accordance and compliance with the guidelines and regulations of the
Canadian Council on Animal Care (CCAC). All protocols were approved by the
Animal Care Committee of McGill University (protocol number 5287; Principal
Investigator: P. Gros). Mice were anesthetized, and euthanized by carbon dioxide
inhalation, and every effort was made to minimize animal suffering. Sample size to
achieve adequate power was chosen on the basis of previous studies with similar
methods20,31,32. Brieﬂy, a minimum of 3 mice for control animals and between 4 to
7 mice (per experiment) were used for treated animals. We randomized mice from
different cages and different time points to exclude cage or batch variation.
Experiments were not performed in a blinded fashion except when speciﬁcally
indicated. Experiments and data analysis was performed without exclusion criteria,
and all data was retained.
For isolation of human PBMC, informed consent was obtained from all donors
and approved by the governing ethics committee (Comité d’ethique hospital-
facultaire universitaire de Liège; Protocol B70720097536; 2009/256; Principal
Investigator: Prof. E. Louis). For clinical specimens, only disposed de-identiﬁed
segments of surgical specimens from patients undergoing bowel resection as part of
their medical care for ulcerative colitis, Crohn’s disease or colorectal cancer/
diverticulitis (controls)at the Mount Sinai Medical Center had been used in this
study. The obtained specimens were pathological waste and used for research
purposes only. Surgical wastes were completely anonymous and patient’s identiﬁers
had never been communicated to the research team in order to strictly maintain
patient’s conﬁdentiality. Once unidentiﬁed specimens arrived in the laboratory,
they were given lab accession numbers, which were not linked to any of the patient
identiﬁers directly or indirectly. Because of the above process, the institutional
review board at the Mount Sinai Medical Center considered this study as being
“none human subject” research which fell under the waiver of the Consent Process.
As a result, consent forms were not required for this study.
Mice. Wild type C57BL/6 J, Ccdc88bm1PGrs (Ccdc88bmut)5 and Rag1−/− (RAG)
mutant male mice (on B6 background), 8 to 10 weeks of age were obtained from
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the Jackson Laboratory (Bar Harbor, ME) and were housed under speciﬁc
pathogen-free conditions at the animal care facility of the Goodman Cancer
Research Centre, McGill University. The animal studies were conducted under
protocols approved by the McGill Institutional Review Board (protocol number
5287), and following guidelines and regulations of the Canadian Council of Animal
Care.
Mouse models of intestinal colitis. To induce colitis mice (8 weeks old, male)
were fed 3% (w/v) DSS (dextran sodium sulfate; molecular mass 36–40 kDa; MP
Biomedicals) in the drinking water for 5 days. This was followed by normal
drinking water until day 8, at which point animals were sacriﬁced. Mice were co-
housed at weaning until the start of the experiment. The animals were weighed
daily and monitored for signs of distress. For T cell transfer-induced colitis, naive
CD4+ CD45RBhi T cells from WT or Ccdc88bmut mice were enriched (CD4+T Cell
Isolation Kit; Miltenyi Biotec) and single-cell suspensions were stained with anti-
body dilutions 1:300 FITC-anti-CD4 (GK1.5), 1:250 PE-anti-CD25 (PC61.5) and
1:1500 APC–anti-CD45RB (C363.16 A), all from eBioscience33, following pur-
iﬁcation (>99%) by cell sorting (FACSAriaII). Sex-matched Rag1−/− recipient mice
received 5 × 105 CD4+ CD45RBhi T cells by intravenous (i.v.) injection. Mice were
sacriﬁced when symptoms of clinical disease (signiﬁcant weight loss) became
apparent in control mice receiving WT cells, ~7 weeks after injection.
Lamina propria cell preparation and ﬂow cytometry analysis. Colons were
collected from control and DSS-treated mice and tissues were dissociated with
Lamina Propria Dissociation Kit, (Miltenyi Biotec), according to the manufacturer
instructions. Single-cell suspensions were prepared and cells were ﬁrst stained with
vital dye Zombie Aqua™ dye (at 1/400 dilution) (Biolegend) then surface stained
with the following ﬂuorescently-labeled antibodies: 1:300 PerCP-Cy5.5-Ly6G
(1A8), 1:200 PE-Dazzle 594-CD3 (17A2), 1:100 BV421-Ly6C (HK1.4) all from
Biolengend, 1:300 PE-Cy7-CD4 (GK1.5), 1:200 APC-NK1.1 (PK136), 1:200 Alexa
700-CD8 (53–6.7), 1:300 Evolve 605-CD11b (M1/70) and 1:300 APC-Eﬂuor-780-
CD45 (30-F1) all from eBiosicense. After permeabilization, cells were stained with
rabbit anti-mouse Ccdc88B and anti-rabbit Alexa 488. Stained samples were
analayzed on a Fortessa ﬂow cytometer (BD Bioscience) and the results analyzed
using FlowJo software (Tree Star Inc.).
Anti-human CCDC88B antibody production and puriﬁcation. Polyclonal rabbit
anti-human CCDC88B antiserum was prepared as we have previously descri-
bed5,34. A recombinant protein consisting of glutathione-S-transferase (GST) fused
in-frame to a CCDC88B segment corresponding to human amino acid positions
650 to 769, was expressed in E. coli BL21, followed by afﬁnity puriﬁcation with
glutathione-agarose beads (GE Healthcare). Antisera were raised in New Zealand
white rabbits using puriﬁed protein (0.5 mg per rabbit per injection) emulsiﬁed in
Freund’s incomplete adjuvant. Afﬁnity puriﬁcation of the anti-CCDC88B anti-
body35 was using a recombinant CCDC88B protein (positions 650 to 769) com-
prising a poly-histidine tail (His)6 fused in-frame at its N terminus, and puriﬁed by
chromatography onto Ni-NTA agarose (Qiagen). The immobilized protein was
used to capture the anti-CCDC88B fraction of the hyperimmune serum, which was
then released by washing with imidazole-containing buffer34. The speciﬁcity of the
anti-CCDC88B antibody was tested by western blotting total cell extracts from
HEK293T control cells and HEK293T cells (ATCC, CRL-11268) stably expressing
a full-length human CCDC88B.
Immunoblotting. Tissue homogenates were prepared in lysis buffer solution
(150 mM NaCl, 20 mM Tris (pH 7.4), 10 mM EDTA, 1.5 mM EGTA and 1%
Nonidet P-40) supplemented with a cocktail of protease inhibitors; 50 mM NaF,
10 mM of Na4P2O7;1 mM Na3VO4 in addition to 1X of protease inhibitor cocktail
tablet (Roche) using a Polytron Homogenizer (Kinematica AG). Samples were
clariﬁed, denatured with SDS buffer, and boiled for 5 min. Proteins were separated
by SDS-PAGE and transferred on Immobilon®-P PVDF Membrane (Millipore).
The membranes were immunoblotted with primary rabbit anti-mouse or rabbit
anti-human CCDC88B antibodies followed by detection with anti-rabbit
antibodies.
Immunohistochemistry. For Ki-67 staining, formalin-ﬁxed parafﬁn-embedded
tissue sections were de-waxed and rehydrated, incubated in Diva Decloaker antigen
retrieval solution (Biocare) and boiled for 20 min in a pressure cooker. Peroxidase
activity was blocked using the Enzyme Block for 15 min (DAKO). Slides were
stained with 1:400 anti-Ki-67 (D3B5; Cell signaling) for 1 h followed by another
hour of incubation with 1:500 of goat anti-rabbit (Jackson laboratories). Finally,
slides were incubated with DAKO DAB substrate (DAKO) for 10 min and counter-
stained with hematoxilin, then mounted. For Alcian Blue staining (1% solution,
Sigma), slides were stained at room temperature for 30 min and then washed. Cell
nuclei were stained with Kernchtrot Nuclear Fast Red stain (1 min). Slides were
washed with distilled water, dehydrated with anhydrous alcohol and mounted.
Immunoﬂuorescence. Tissues for cryopreservation were ﬁxed in 4% paraf-
ormaldehyde (PFA) for 6 h, incubated in 20% sucrose overnight, and frozen in
Optimal Cutting Temperature (OCT) medium (VWR International). For immu-
noﬂuorescence, frozen sections (7 µm) were washed in phosphate-buffered saline
(PBS), incubated in blocking buffer (10% BSA, 0.4% Triton-X-100 in PBS) for 1 h
at room temperature, and then incubated with primary antibody in primary
antibody solution (1% BSA, 0.4% Triton-X-100) in phosphate-buffered saline
(PBS) for 1 h at room temperature or overnight at 4 °C. The primary antibodies
and dilutions used were as follows: 1:200 rabbit antiCcdc88b5, 1:100 rat anti-CD3ε-
FITC (145-2C11, BioLegend), 1:100 rat anti-CD11b-APC (M1/70, eBioScience),
1:100 rat anti-CD4-FITC (GK1.5, BioLegend) 1:100 rat anti-CD8-FITC (53–6.7),
BioLegend) 1:100 rat anti-E-Cadherin-660 (DECMA-1, eBioScience), 1:100 rat α-
CD45-PE (30-F11, eBioScience). Bound antibodies were detected using a 1:1000
dilution of rabbit anti-Cy3, or AlexaFluor488. Immunostained sections were
counterstained with 4′,6-diamidino-2-phenylindole (DAPI) at a 1:3000 or Hoechst
at 1:5000 to visualize the nuclei. Images were acquired on a Zeiss LSM710 Meta
Laser Scanning Confocal microscope or Axioscope 2 plus, processed with ImageJ,
and compiled with Adobe Illustrator. Parafﬁn-embedded sections of NL, CD and
UC specimens were heat treated in citrate buffer (pH 6) for 10 min at 121 °C for
antigen retrieval. The section were blocked with 10% normal human serum in PBS
for 1 h at room temperature. Slides were stained with a combination of 1:100 rabbit
anti-hCCDC88B and 1:150 mouse anti-CD68 (KP1, Abcam) or mouse 1:100 anti-
CD4 (N1UG0, Afﬁmetrix) to assess colocalization or 1:150 rabbit anti-CD3 (SP7,
Abcam) and rabbit anti-CD8 (NBP2-29475, Novus Biologicals). Bound antibodies
were revealed using a dilution of 1:500 of mouse anti-AlxaFluor 488 or rabbit anti-
AlxaFluor 647 and counterstained with DAPI. Images were aquiered using
Olympus VS110 systems and analyzed and processed with Olyvia software
(Olympus).
Gene expression and cytokine quantitation in colon tissues. RNA was puriﬁed
using a FastPrep 24 homogenizer (MP Biomedicals) with lysing matrix D beads
(MP Biomedicals) and RNAeasy kits (QIAGEN). RNA purity and quantiﬁcation
was determined using a Nanodrop spectrophotometer (Nanodrop Technologies).
cDNA synthesis was performed using a MMLV reverse transcriptase with a
cocktail of Oligo dT and random hexamers (Invitrogen). Human and mouse
Ccdc88b mRNA expression were quantiﬁed using the following primer sets,
mCcdc88b (5′-CCGGGAGCTTCGAGGCCAAC-3′ and 5′-CCTATCTGGCAAG
CGGGGC-3′) and h-CCDC88B (5′-GCGTGAGGGGTCCAGGC-3′ and 5′-CTCC
TTGCCCCGCACCAC-3′). Cytokines and chemokines were quantiﬁed by RT-
qPCR using Perfecta SYBR Green PCR kit and the speciﬁc primers sets mMCP-1/
CCL2 (5′-AGGTGTCCCAAAGAAGCTGTA-3′ and 5′-TCTGGACCCATTCC
TTCTTG-3′), KC/ CXCL1 (5′-CACCTCAAGAACATCCAGAGC-3′ and 5′-CTTG
AGTGTGGCTATGACTTCG-3′), mIL1-β (5′-CGGCACACCCACCCTG-3′, and
5′- AAACCGCTTTTCCATCTTCTTCT-3′) mTNF- (5′-TCTCAGCCTCTTCTCA
TTCC-3′ and 5′-AGAACTGATGAGAGGGAGGC-3′), mIL-6 (5′-GAAGTAGGG
AAGGCCGTGG-3′ and 5′-GAAGTAGGGAAGGCCGTGG-3′), mRantes/ CCL5
(5′-GCAAGTGCTCCAATCTTGCA-3′ and 5′-CTTCTCTGGGTTGGCACACA-
3′), hIL-8 (5′-CTGGCCGTGGCTCTCTTG-3′) and (5′CTTGGCAAAACTGCAC
CTTCA-3′). Gene expression was normalized to hL32 expression (5′-TGTCCTGA
ATGTGGTCACCTGA-3′ and 5′-CTGCAGTCTCCTTGCACACCT-3′) and
mHprt (5′-TCAGTCAACGGGGGACATAAA-3′ and 5′-GGGGCTGTACTGCTT
AACCAG-3′) and relative expressions calculated using the ΔΔCT method. Serum
was prepared from blood of DSS-treated animals. MCP-1/CCL2 and KC/CXCL1
chemokine were quantiﬁed by ELISA (R&D Systems) according to the manu-
facturer’s protocol.
Assessment of intestinal inﬂammation. At experimental endpoints, the entire
colons were excised, and their length measured. Colons were ﬁxed overnight in
10% PFA, embedded in parafﬁn, and 4 μm sections were stained with hematoxylin
& eosin. Histology was evaluated blindly by a pathologist to avoid bias. For DSS-
induced colitis, histology was scored from 0 to 4 for a combination of inﬂammatory
cell inﬁltration, surface epithelial erosion / ulceration, and gland loss for a total
score of 24. For the transfer of naive CD4+T cells, histology was scored from 0 to 4
for the following criteria; inﬂammatory cell inﬁltration, inﬂammatory cell depth,
submucosal edema, increased mucosal thickening, surface epithelial degeneration,
gland epithelial apoptosis, gland epithelial degeneration/abscesses, gland goblet/
enterocyte ratio decrease, submucosal edema and gland loss for a total score of 36
(detailed pathology scoring in Supplementary Table 1).
Clinical specimens. Disposed anonymous surgical specimens from patients
undergoing bowel resection for Crohn’s disease, ulcerative colitis or colorectal
cancer/diverticulitis (controls) at the Mount Sinai Medical Center were acquired as
previousely published36,37. Both inﬂamed CD or UC, and non-inﬂamed controls
were used. RNA was extracted from frozen colonic specimens corresponding to
active Crohn’s Disease (CD) and Ulcerative Colitis (UC) mucosal tissue along with
adjacent normal tissue (Adj, >10 cm from the lesion) from the same patients.
Expression-QTL analyses and data. EDTA-treated blood from 320 individuals
were layered on Ficoll-Paque PLUS (GE Healthcare) for isolation of peripheral
blood mononuclear cells by density gradient centrifugation. CD4+, CD8+, CD19+,
CD14+, and CD15+ cells were isolated using MicroBead Technology (Miltenyi
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Biotec). Total RNA was isolated using the AllPrep Micro Kit on a QIAcube robot
(Qiagen). Whole genome expression data were generated for each of the cell/tissue
types on Illumina Human HT-12 Expression BeadChips. 8,537 out of 47,231
probes mapping to multiple locations or encompassing known SNPs with
MAF≥0.05 were eliminated from further analyses. Raw ﬂuorescent intensities were
variance stabilized38 and quantile normalized39 using lumi R package40. Normal-
ized expression data were corrected for Sentrix ID (random effect), age, sex,
smoking status, and number of probes exceeding the detection limit (ﬁxed effects
and covariates, if signiﬁcant (p≤ 0.05) using a mixed model implemented with
lme4 R package. eQTL analyses were performed using PLINK.
Genetic association between CD and CCDC88B expression. The correlation
between the genetic association with gene expression level and disease assumes
that; (a) genetic variant(s) in a given chromosome region affect the levels of
expression of gene(s) in that region and that this affects predisposition to a given
disease (CD in this study), one can predict that the corresponding association
patterns (i.e. the set of log(1/p) values of association for the SNPs in the region with
CD and gene expression, respectively) will be positively correlated. Such positive
correlation can correspond to two distinct scenarios: increased gene expression
may either be associated with increased or decreased disease risk. This information
can be captured by calculating the correlation between log(1/p) values multiplied
by the sign of the corresponding genetic effects (β). To avoid that the ensuing
metric would be sensitive to the choice of the reference allele, we duplicate each
data point in the correlation analysis, respectively considering the two alleles as
reference in the association analysis. In summary, we generate a correlation metric,
D(isease)E(xpression)C(orrelation), corresponding to:
DEC ¼ Pen ´ SC x; yð Þ ð1Þ
Pen is a penalty function that measures the strength of the positive correlation
between the log(1/p) values for the disease and eQTL associations respectively. Pen
is deﬁned as:
Pen ¼ 1= 1þ ek1 ´ σðx;yÞk2ð
 
ð2Þ
σ(x,y) corresponds to Spearman’s rank correlation between the log(1/p) values of
associations with disease and gene expression for the SNPs in the region, and k1
and k2 to constants that determine the severity of the penalty, and which were
empirically set at 30 and 0.3, respectively, in this study. We restrict the analysis to
“informative” SNPs that have a log(1/p) value >1.2 for either the disease, or the
eQTL or both. SC(x,y) stands for “signed correlation”. It corresponds to Spear-
man’s rank correlation between two pairs of sign_β*log(1/p) values for each SNP in
the studied region. The ﬁrst pair corresponds to the log(1/p) values multiplied by
the sign of the effect of the association on disease and gene expression, respectively,
assuming allele 1 as reference. The second pair is identical but assumes allele 2 as
reference. We restrict the analysis to “informative” SNPs that have a log(1/p) value
>1.2 for either the disease, or the eQTL or both.
To measure the statistical signiﬁcance of the observed DEC, yet accounting for
the LD structure of the studied region, we generated as many eQTL as there are
SNPs in the studied region in silico. The in silico eQTL are simulated such that they
explain the same variance as the true eQTL. For each simulated eQTL with
compute a corresponding “simulated DEC”. The statistical signiﬁcance of the
actual DEC is then measured as the number of simulated DEC that are as large or
larger than the true DEC. The log(1/p) values for CD were directly obtained from1.
The log(1/p) values for the eQTL were obtained from the dataset described above.
Statistical analysis. Results are presented as mean±SEM. Prism5 (GraphPad)
software was used for all statistical tests. Statistical signiﬁcance was determined by
two-tailed Student’s t-test for comparison of two groups and Mann–Whitney test
for intestinal scoring41, unless otherwise indicated. Differences were considered
statistically signiﬁcant when P≤ 0.05. P-values are indicated by *P< 0.05, **P<
0.01, ***P< 0.001.
Data availability. The data that support the ﬁndings of this study are available
within the article, its Supplementary Information ﬁles and from the corresponding
author upon reasonable request.
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